Constant Therapeutics Revenue

About Constant Therapeutics

Constant's lead drug candidate, TXA127, is a pharmaceutical formulation of the natural human peptide, angiotensin-(1-7) [Ang-(1-7)]. Ang-(1-7), the active ingredient in Constant’s product, TXA127, has been shown to have multiple biologic effects: -stimulating endothelial progenitor cells -stimulating muscle satellite cells -stimulating oligodendrocyte progenitor cells -reducing oxidative stress and ROS, -restoring the integrity of epithelial and endothelial surfaces, -reducing inflammation by reversing the increased permeability of the blood vessels caused by the virus; thereby preventing movement of inflammatory cells into tissue leading to the “cytokine storm,” -reducing apoptosis, -inhibiting coagulopathy, and -reducing fibrosis through down-regulation of the TGF beta pathway. Ang-(1-7) has been shown to have positive outcomes in a number of animal models of stroke, heart disease, and muscle dystrophies. In addition, in several disease models it has become clear that blocking the effect of Ang-(1-7) is detrimental.

View contact profiles from Constant Therapeutics